Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 13 studies | 37% ± 16% | |
lung | 6 studies | 28% ± 11% | |
heart | 6 studies | 44% ± 21% | |
peripheral blood | 5 studies | 19% ± 1% | |
eye | 5 studies | 41% ± 15% | |
kidney | 5 studies | 27% ± 3% | |
adipose | 4 studies | 44% ± 20% | |
liver | 3 studies | 30% ± 11% | |
lymph node | 3 studies | 18% ± 4% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
ovary | 100% | 3688.44 | 180 / 180 | 100% | 12.11 | 430 / 430 |
lung | 100% | 4051.97 | 577 / 578 | 100% | 11.89 | 1155 / 1155 |
breast | 100% | 4777.01 | 459 / 459 | 99% | 10.48 | 1112 / 1118 |
intestine | 100% | 2874.78 | 965 / 966 | 99% | 9.20 | 523 / 527 |
prostate | 100% | 2322.34 | 244 / 245 | 99% | 7.62 | 499 / 502 |
stomach | 100% | 2134.01 | 359 / 359 | 99% | 10.08 | 283 / 286 |
thymus | 100% | 3646.43 | 652 / 653 | 99% | 8.30 | 596 / 605 |
bladder | 100% | 4126.14 | 21 / 21 | 98% | 8.20 | 495 / 504 |
esophagus | 97% | 2129.27 | 1402 / 1445 | 100% | 13.85 | 183 / 183 |
skin | 99% | 2766.43 | 1797 / 1809 | 97% | 10.46 | 459 / 472 |
uterus | 99% | 2637.72 | 169 / 170 | 96% | 8.45 | 442 / 459 |
kidney | 100% | 1824.62 | 89 / 89 | 95% | 8.49 | 859 / 901 |
adrenal gland | 100% | 2450.75 | 258 / 258 | 87% | 4.44 | 201 / 230 |
pancreas | 80% | 826.00 | 263 / 328 | 99% | 11.95 | 176 / 178 |
liver | 88% | 958.68 | 200 / 226 | 77% | 3.70 | 311 / 406 |
brain | 53% | 1108.74 | 1399 / 2642 | 99% | 7.45 | 695 / 705 |
adipose | 100% | 6432.82 | 1204 / 1204 | 0% | 0 | 0 / 0 |
spleen | 100% | 3232.29 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 9.22 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 5.10 | 1 / 1 |
blood vessel | 100% | 3371.05 | 1334 / 1335 | 0% | 0 | 0 / 0 |
heart | 98% | 3452.48 | 844 / 861 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 97% | 13.21 | 28 / 29 |
muscle | 90% | 1618.02 | 721 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 72% | 1920.83 | 667 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 60% | 2.80 | 48 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0016567 | Biological process | protein ubiquitination |
GO_0050860 | Biological process | negative regulation of T cell receptor signaling pathway |
GO_0035739 | Biological process | CD4-positive, alpha-beta T cell proliferation |
GO_0007165 | Biological process | signal transduction |
GO_0050852 | Biological process | T cell receptor signaling pathway |
GO_2000583 | Biological process | regulation of platelet-derived growth factor receptor-alpha signaling pathway |
GO_0006955 | Biological process | immune response |
GO_0045732 | Biological process | positive regulation of protein catabolic process |
GO_0035556 | Biological process | intracellular signal transduction |
GO_0002870 | Biological process | T cell anergy |
GO_0030163 | Biological process | protein catabolic process |
GO_0031398 | Biological process | positive regulation of protein ubiquitination |
GO_0007175 | Biological process | negative regulation of epidermal growth factor-activated receptor activity |
GO_0002669 | Biological process | positive regulation of T cell anergy |
GO_0006607 | Biological process | NLS-bearing protein import into nucleus |
GO_2000562 | Biological process | negative regulation of CD4-positive, alpha-beta T cell proliferation |
GO_0005886 | Cellular component | plasma membrane |
GO_0045121 | Cellular component | membrane raft |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0061630 | Molecular function | ubiquitin protein ligase activity |
GO_0008270 | Molecular function | zinc ion binding |
GO_0001784 | Molecular function | phosphotyrosine residue binding |
GO_0005509 | Molecular function | calcium ion binding |
GO_0005515 | Molecular function | protein binding |
GO_0030971 | Molecular function | receptor tyrosine kinase binding |
GO_0017124 | Molecular function | SH3 domain binding |
Gene name | CBLB |
Protein name | E3 ubiquitin-protein ligase CBL (EC 2.3.2.27) E3 ubiquitin-protein ligase CBL-B (EC 2.3.2.27) (Casitas B-lineage lymphoma proto-oncogene b) (RING finger protein 56) (RING-type E3 ubiquitin transferase CBL-B) (SH3-binding protein CBL-B) (Signal transduction protein CBL-B) Cbl proto-oncogene B |
Synonyms | Nbla00127 RNF56 |
Description | FUNCTION: E3 ubiquitin-protein ligase which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and transfers it to substrates, generally promoting their degradation by the proteasome. Negatively regulates TCR (T-cell receptor), BCR (B-cell receptor) and FCER1 (high affinity immunoglobulin epsilon receptor) signal transduction pathways. In naive T-cells, inhibits VAV1 activation upon TCR engagement and imposes a requirement for CD28 costimulation for proliferation and IL-2 production. Also acts by promoting PIK3R1/p85 ubiquitination, which impairs its recruitment to the TCR and subsequent activation. In activated T-cells, inhibits PLCG1 activation and calcium mobilization upon restimulation and promotes anergy. In B-cells, acts by ubiquitinating SYK and promoting its proteasomal degradation. Slightly promotes SRC ubiquitination. May be involved in EGFR ubiquitination and internalization. May be functionally coupled with the E2 ubiquitin-protein ligase UB2D3. In association with CBL, required for proper feedback inhibition of ciliary platelet-derived growth factor receptor-alpha (PDGFRA) signaling pathway via ubiquitination and internalization of PDGFRA (By similarity). . FUNCTION: E3 ubiquitin-protein ligase which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and transfers it to substrates, generally promoting their degradation by the proteasome. . FUNCTION: E3 ubiquitin-protein ligase which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and transfers it to substrates, generally promoting their degradation by the proteasome. . FUNCTION: E3 ubiquitin-protein ligase which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and transfers it to substrates, generally promoting their degradation by the proteasome. . FUNCTION: E3 ubiquitin-protein ligase which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and transfers it to substrates, generally promoting their degradation by the proteasome. . FUNCTION: E3 ubiquitin-protein ligase which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and transfers it to substrates, generally promoting their degradation by the proteasome. . FUNCTION: E3 ubiquitin-protein ligase which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and transfers it to substrates, generally promoting their degradation by the proteasome. . FUNCTION: E3 ubiquitin-protein ligase which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and transfers it to substrates, generally promoting their degradation by the proteasome. . FUNCTION: E3 ubiquitin-protein ligase which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and transfers it to substrates, generally promoting their degradation by the proteasome. . FUNCTION: E3 ubiquitin-protein ligase which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and transfers it to substrates, generally promoting their degradation by the proteasome. . |
Accessions | ENST00000643192.1 A0A2R8Y8D8 ENST00000645759.1 Q13191 ENST00000646499.1 ENST00000405772.5 [Q13191-2] ENST00000443752.2 C9JU85 C9JRB3 ENST00000394030.8 [Q13191-1] ENST00000643322.1 A0A2R8Y582 C9K048 A0A2R8Y7I2 ENST00000447441.6 ENST00000438603.6 A0A2R8Y875 ENST00000646825.1 ENST00000642241.1 A0A2R8Y5E1 A0A2R8YFD4 ENST00000643403.1 ENST00000403724.5 [Q13191-3] A0A2R8YDW4 ENST00000645425.1 |